



Constantin Volovăț

Cetățenie: română **Data nașterii:**

Gen: Masculin

E-mail:

EDUCAȚIE ȘI FORMARE PROFESIONALĂ

Studii liceale (Diploma seria A nr 206806)

Liceul industrial " Garabet Ibraileanu" [1974 – 1978]

Localitatea: Iasi

Studii de licență (Diploma seria D nr 1161)

Universitatea de Medicină și Farmacie "Grigore T. Popa", Iași, Facultatea de Medicină [1979 – 1985]

Master „Management și Sănătate Publică” (Diploma seria D nr 0015193)

[2002 – 2004]

Studii doctorale- diplomă de doctor în științe medicale (Diploma seria H nr 0015762)

Universitatea de Medicină și Farmacie "Grigore T. Popa", Iași, Facultatea de Medicină [2012]

Domeniul (domeniile) de studiu: Medicină

Lucrarea de diplomă: Evaluarea calității vieții și a efectelor adverse la pacientele cu cancer mamar tratate cu inhibitori de aromatază- coordonator Prof.dr. Carmen Vulpoi

Formare medicală continuă

Domeniul (domeniile) de studiu: Medicină, management sanitar și cercetare

1. European School of Oncology, Vienna, 1999- Curs de trialuri clinice
2. Royal Marsden Hospital, London, 1999- Glioma Perceptorship program
3. Perspectives in colorectal cancer, 2001, Dublin- curs
4. National Cancer institute, 2006, Bethesda- Immunology of hyperthermia
5. Universitatea de Medicină, Hong Kong, 2007- Good Clinical Practice
6. Universitatea de Medicină, Kiel, 2008- training în tratamentul melanomului
7. Grosslingen Hospital, Munich, 2008- hipertermia în tratamentul cancerului
8. Institutul del Tumori, Milano, 2009- training în cancerul hepatic
9. Școala Națională de Sănătate Publică și Management, București, 2010- curs management spital (MS2)
10. Institute Gustave Roussi, Paris, 2011- training în cancerul mamar
11. Leuven Oncology Institute, 2012- training în cancerul colorectal

EXPERIENȚA PROFESIONALĂ

Medic rezident

[1985 – 1988]

Localitatea: Iasi

Medic de familie

[1989 – 1991]

Localitatea: Comuna Romanesti, jud. Iasi

Medic specialist oncologie medicală (Ordin MS nr 240/18.02.1994)

[1991 – 1994]

Medic primar oncologie medicală (Ordin MS nr 694/1998)

[1998 – În curs]

Medic coordonator pe oncologie pe județul Iasi, Romania

[1994 – 2000]

Practică privată - coordonator Centrul de oncologie

[2001 – 2011]

Localitatea: Iasi

Director Medical - Centrul de oncologie Euroclinic SRL - Victoria Hospital

[2011 – În curs]

Localitatea: Iasi

Experiență trialuri clinice coordonate de FDA

- 2001- 2023: peste 90 de trialuri multicentrice ca investigator principal și 39 de audituri în studii clinice internaționale (Anexa 1).
- Manager și investigator principal la Medical Oncology Center, Iași.
- Trainer "Good Clinical Practice"- Euroclinic Oncology Center

COMPETENȚE LINGVISTICE

Limbă(i) maternă(e): **română**

Altă limbă (Alte limbi):

engleză

franceză

COMPREHENSIUNE ORALĂ C2 CITIT C2 SCRIS C2

COMPREHENSIUNE ORALĂ B2 CITIT B2 SCRIS B2

EXPRIMARE SCRISĂ C2 CONVERSAȚIE C2

EXPRIMARE SCRISĂ B2 CONVERSAȚIE B2

Niveluri: A1 și A2 Utilizator de bază B1 și B2 Utilizator independent C1 și C2 Utilizator experimentat

COMPETENȚE DIGITALE

Microsoft Office (Microsoft) / IBM SPSS (quantitative analysis) / SAS, R Studio, STATA - nivel intermediar

COMPETENȚE DE MANAGEMENT ȘI CONDUCERE**Leadership**

Bune abilități de conducere rezultate dintr-o bază teoretică solidă (master și formare în managementul intraspitalicesc), precum și din experiența practică în calitate de director medical al Centrului de oncologie Euroclinic - Victoria Hospital.

Managementul de proiect pentru numeroase trialuri clinice la nivel internațional.

COMPETENȚE DE COMUNICARE ȘI INTERPERSONALE**Comunicare interpersonală și mentorat**

- Spirit de echipă
- Adaptare rapidă într-o comunitate multiculturală
- Formarea unor generații de tineri oncologi

PERMIS DE CONDUCERE

Permis de conducere: B

RETELE ȘI AFILIERI

Membru în diferite societăți de profil din țară și străinătate

1. Membru Societatea de Medici și Naturaliști Iași (1990)
2. Membru Societatea Română contra durerii (1993)
3. Membru fondator Liga de Luptă contra Cancerului Moldavia (1994)
4. Membru fondator al Societății Române de Oncologie Medicală (1997)
5. Membru Balkan Union of Oncology (1998)
6. Membru American Society of Clinical Oncology (2001)
7. Membru European Society of Hyperthermia (2007)
8. Membru European Society of Medical Oncology (2008)
9. Membru Multinational Association of Supportive Care in Cancer (2011)

PUBLICAȚII

Articole științifice indexate în Web of Science Core Collection (peste 40 de articole ISI)

Anexa 2

Cărți și capitole de carte

1. Volovat C, Volovat SR. „Evaluarea pacientului onco-geriatric: particularitati terapeutice”. In: Ioana Dana Alexa „Actualitati in geriatrie”. Editura „Gr. T. Popa” UMF Iasi 2011; pg 237-245 (ISBN 978-606-544-077-7)
2. C VOLOVAT, S VOLOVAT. „Obezitatea si cancerul mamar”. În: Carmen Vulpoi, Voichița Mogoș, Crisina Preda „Actualități in Endocrinologia Oncologică. Sillabus”. Editura „Gr. T. Popa”, UMF Iași 2014; pg: 163-170 (ISBN 978-606-544-233-4)
3. Cătălin Pricop, Dan Mischianu, Orsolya Martha. Cancerul de prostată local avansat și metastazant Editura PIM, 2015: 322-341. (ISBN 978-606-13-2779-9)
4. Volovat, C., Volovat, SR: Update în oncology. Editura „Gr. T. Popa”, UMF Iași 2019 (2 vol) (ISBN 978-606-544-615-1/ 978-606-544-672-4)
5. Volovat, C., Volovat, SR., Agop, M. (2022). Nanotechnology and Immunomodulators in Cancer. In: Kesharwani, R.K., Keservani, R.K., Sharma, A.K. (eds) Immunomodulators and Human Health. Springer, Singapore. https://doi.org/10.1007/978-981-16-6379-6_5 (ISBN 978-981-16-6378-9)

Conferințe/Congrese

Anexa 3

04 SEP 2023



Anexa 1 CV- studii clinice

1. "A Multicentre Phase III Trial of Docetaxel and Doxorubicin in patients with unresectable locally advanced breast cancer"
2. "Phase III Gemcitabine plus Epirubicin plus Taxol (GET 75) in Advanced Breast Cancer"
3. "A Phase II study of Paclitaxel (Taxol) and Carboplatin treatment given every 2 nd week to previously untreated patients with FIGO stage III ovarian cancer"
4. "A Phase IV Study of Gemcitabine plus Cisplatin in The Treatment of Metastatic Bladder Cancer"

STUDII CLINICE perioada 2000 – 2019 (fază II și III multinaționale, multicentrice sub egida FDA/EMA)

CRO - PAREXEL International Romania s.r.l.

1. - phase II/III study - " A double blind, randomized, parallel group, placebo controlled, comparative study of efficacy, safety and tolerability of cannabis based medicine extracts (CBME) in patients with cancer-related pain" Protocol GWCA0101 , CRO-PAREXEL jan 2003 – mar 2004
- 2.- A Randomized, Multicenter, Open-Label, Phase II/III Study With the Intraperitoneally Infused Trifunctional Bispecific Antibody Removab(TM) (Anti-EpCAM x Anti-CD3) in Patients with Malignant Ascites , CRO-PAREXEL oct.2004-nov.2005,
3. – phase II/III study – "Efficacy and safety of XXX compared with filgrastim in patients with non-small cell lung cancer receiving chemotherapy with platinum compounds" dec 2004 – may 2005 , CRO-PAREXEL
- 4 - "Phase II Study Comparing 5FU/FA Plus Oxaliplatin Plus Cetuximab vs 5-FU/FA Plus Oxaliplatin as First-Line Treatment for EGFR-Expressing Metastatic Colorectal Cancer" feb.2006 – may 2006 , CRO-PAREXEL
- 5.A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer, 2005-2007
6. A Randomized, Open-Label, Multicenter, Phase 3 Study of Epoetin Alfa plus Standard Supportive Care versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving First-Line Standard Chemotherapy Protocol: EPO-ANE-3010 2005-2010
7. Phase III Multicenter, Randomized, Double-Blind, Chemo-therapy-Induced Nausea and Vomiting in Cancer Subjects 2007- 2009
8. - "Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab vs. 5FU/FA Plus Irinotecan as First-Line Treatment for EGFR-Expressing Metastatic Colorectal Cancer" aug 2005 – dec 2005 , CRO-PAREXEL 9.- "Phase II Study – "Efficacy and safety of XM-01



compared to placebo and Epoetin beta in patients with solid tumours receiving platinum – containing chemotherapy” jan 2006 – aug 2006 , CRO-PAREXEL

10.- “Phase II Study - “Efficacy and safety of XM-01 compared to placebo and Epoetin beta in patients with solid tumours receiving non-platinum – containing chemotherapy” jan 2006 – may 2006 , CRO-PAREXEL

11. - Study 07-IN-NX003 - A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC) 2007-2010, CRO-PAREXEL

12. AVI-014-P02 An Open-Label, Dose Finding, Prospective, Multi Center, Randomized, Parallel Group Study to Assess the Efficacy and Safety of Three Different Dose Levels of AVI 014 (GCSF) Compared With a Standard Dose of Neupogen® in Breast Cancer Patients at High (>20%) Risk for Chemotherapy Induced Severe Neutropenia , CRO-PAREXEL 2007 - 2009

13. Open-Label, Randomized, Controlled, Multicenter Phase III Study Investigating Cetuximab in Combination With Capecitabine (Xeloda, X) and Cisplatin (P) Versus XP Alone as First-Line Treatment for Subjects With Advanced Gastric Adenocarcinoma Including Adenocarcinoma of the Gastroesophageal Junction , CRO-PAREXEL 2008 - 2009

14. A Study to Evaluate the Effects of Afibercept on QTc Interval in Cancer Patients (QUTIE) 2009-2010

15. A Phase II multicenter, parallel group, randomized study of pallfosfamide tris plus doxorubiCin versus doxorubicin in subjects with unresectAble or metastatic Soft-tissue SarcOma (PICASSO) -start – jan 2009 - 2010

16. Phase 2 Randomized Study of Carboplatin/Paclitaxel With or Without CS-7017 in Chemotherapy-Naïve Subjects With Metastatic Non-Small Cell Lung Cancer 2009-2011

17. SQUIRE- A Randomized, Multicenter, Open-Label, Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus IMC-11F8 Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Squamous Stage IIIb or IV Non-Small Cell Lung Cancer (NSCLC) 2009- 2011

18. Multicentre, randomized, double-blind, Phase III trial to investigate the efficacy and safety of oral BIBF 1120 plus standard docetaxel therapy compared to placebo plus standard docetaxel therapy in patients with stage IIIB/IV or recurrent non-small cell lung cancer after failure of first-line chemotherapy.LUME-LUNG 2009-2011

19. Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy 2010 – 2017

20. Phase III, Open-label Study of Nilotinib Versus Imatinib in GIST Patients (ENESTg1) 2010 – 2016

21. Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) 2011 – 2015 22. A Study of Ramucirumab (IMC-1121B) Drug Product (DP)



and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib (REACH) 2011- 2016

23. Neugranin in Breast Cancer Patients Receiving Doxorubicin/Docetaxel (NEUGR-003) 2010 – 2016

24. A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine (RAINBOW) 2012-2014

25. Single-dose, Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group Study to Assess the Efficacy and Safety of Oral Palonosetron 0.50 mg Compared to I.V. Palonosetron 0.25 mg Administered With Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Cisplatin-based Chemotherapy 2012-2016

26. Studiu randomizat, paralel, dublu-orb, care compara eficacitatea si siguranta FKB238 cu Avastin in linia 1 de tratament a pacientilor cu cancer pulmonar non-microcelular avansat/recurent tratati cu paclitaxel si carboplatin – AVANA- FKB238-002 2016-2018

27. A Phase III, Randomised, Double-blind, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB8 (proposed bevacizumab biosimilar) and Avastin® in Subjects with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer. EudraCT No: 2015-004026-34 - SB8-G31-NSCLC 2016-2018

CRO – ABCRo

28. A Randomized, Double-blind, Phase 3 Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma (STA-4783 08) (Synta) 2004-2006

CRO – CRC INTERNATIONAL - WYETH International

29. - “A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 (temsirolimus) Administered in Combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer” - Protocol Number 3066A1-303WW jan 2005- dec 2005 , - CRO – WYETH INTERNATIONAL

CRO - M&M Clinical Research Enterprise Ltd. (group IMITIS)

30. - phase III study – “Symptomatic malignant ascites using paracentesis plus the tri-functional antibody” - period – oct 2005-2009 CRO - M&M Clinical Research Enterprise Ltd. (group IMITIS) 31. - “A Phase III Clinical Study of treatment with Thym-Uvocal vs. Placebo in Metastatic Colorectal Carcinoma” - period - oct 2005 – feb 2006 CRO - M&M Clinical Research Enterprise Ltd. (group IMITIS)

32. Multicentric, Randomized, Placebo Controlled and Double-Blind Study to Evaluate the Efficacy and Safety of Antithrombotic Prophylaxis With Bemiparin (3,500 UI/Day) in Cancer

Patients With a Central Venous Catheter (CVC)(BECAT) -start 2008 -2009 CRO - M&M Clinical Research Enterprise Ltd. (group IMITIS)

CRO - PSI PHARMA SUPPORT

33.- "A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly XXX Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer" - period - jan 2006 – aug 2006 CRO - PSI PHARMA SUPPORT

34. A Randomized, Controlled Phase III Trial of Picoplatin and BSC Versus BSC Alone in Patients With Small Cell Lung Cancer (SCLC), Refractory or Progressive Within Six Months of Completing First-Line, Platinum-Containing Chemotherapy -start 2007 2009 , CRO - PSI PHARMA SUPPORT

35. A Phase 3 Study of Safety and Efficacy of Karenitecin Versus Topotecan Administered for 5 Consecutive Days Every 3 Weeks in Patients With Advanced Epithelial Ovarian Cancer - start 2008-2010 CRO - PSI PHARMA SUPPORT

36. A Phase 2b, Double-Blind, Randomized Study Evaluating the Efficacy and Safety of Sorafenib Compared With Placebo When Administered in Combination With Chemotherapy (Modified FOLFOX6) for the Treatment of Metastatic Colorectal Cancer in Subjects Who Have Not Been Previously Treated for Stage IV Disease

Start – 2009- 2010 CRO - PSI PHARMA SUPPORT

CRO - JOHNSON & JOHNSON

37. A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL®/CAELYX® and Docetaxel for the Treatment of Advanced Breast Cancer - period - jan.2006 – sep.2006 CRO - JOHNSON & JOHNSON

38. - "Phase III A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects with Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia" - period – mar 2007 – 2010 CRO - JOHNSON & JOHNSON

CRO - PRA INTERNATIONAL

39. - "A Phse II Study for immunological evaluation, efficacy adn safety of treatment with HER 2 AUTO VAC Protein + STIMULON ADJUVANT QS-21 in monotherapy at pacients with metastatic breast cancer" - Protocol PX104.1.7-202 - period - jan 2005 – may 2005 CRO - PRA INTERNATIONAL 40. - "A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of XXX vs Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy" - period - jan 2007 – 2011 CRO - PRA INTERNATIONAL

41. - "Phase II Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies" - period - apr 2007 – 2010 CRO - PRA INTERNATIONAL



42. - "Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC)" - start - jun 2007 – 2019 CRO - PRA INTERNATIONAL

CRO - GLAXO SMITHKLINE

43. A Phase III Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel Group Study of the Efficacy and Safety of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagonist, Casopitant, Administered in Combination With ZOFRAN and Dexamethasone for Prevention of Chemotherapy-Induced Nausea and Vomiting in Cancer Subjects Receiving Highly Emetogenic Cisplatin-Based Chemotherapy - period – jan 2007 – 2010 CRO - GLAXO SMITHKLINE

44. - "A Randomised Study , Open Label, multicentric, phase III, for comparing the activity of Lapatinib monotherapy, Trastuzumab monotherapy, sequential therapy with Trastuzumab followed by Lapatinib and concomitant treatment with Lapatinib and Trastuzumab , as adjuvant treatment in patients with breast cancer with hiperexpression of Erb B2 and/or Erb B2 amplification" - Studiul Clinic EGF106708 – ALTO CRO - GLAXO SMITHKLINE - beginning - jun 2006-2018 CRO - GLAXO SMITHKLINE

45. VEG108838 - A Randomized, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Versus Lapatinib Monotherapy in Patients With ErbB2 Over-Expressing Inflammatory Breast Cancer -start 2008 – 2010 CRO - GLAXO SMITHKLINE

CRO - PHARMANET ROMANIA

46.- "Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with Breast Cancer" - period – may 2007 – 2010

47. CT4002 - An Open-Label, Randomized, Controlled Phase-II Trial Evaluating the Efficacy and Safety of EndoTAG-1 in Triple Receptor Negative Breast Cancer Patients -start 2008 - 2010

CRO - COVANCE ROMANIA

48. ATLAS : A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic NonSmall Cell Lung Cancer Start – jun 2007

49. BETA : A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy Start – jun 2007

50. RADIANT: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-Small Cell Lung Carcinoma Who Have EGFRPositive Tumors -start 2008



51. STORM - Bayer HCC (Study Number: 12414): A Phase III randomized, double-blind, placebocontrolled study of sorafenib as adjuvant treatment for hepatocellular carcinoma after surgical resection or local ablation

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy (SAVE-ONCO) periodoada 2008 - 2010

CRO - PPD

52. - A Randomized, Double-Blind, Phase 3 Trial of Elesclomol (STA-4783) in Combination With Paclitaxel Versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects With Stage IV Metastatic Melanoma (SYMMETRY) -Start 2008

53. - A Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial of AMG 706 in Combination With Paclitaxel and Carboplatin for Advanced Non-Small Cell Lung Cancer Start date : may 2008 – 2011

CRO – INC Research

54. A Randomized Withdrawal, Active- and Placebo-Controlled, Double-Blind, Multi-Center Phase III Trial Assessing Safety and Efficacy of Oral CG5503 PR* in Subjects With Moderate to Severe Chronic Malignant Tumor-Related Pain -start 2007-2013

CRO – Quintiles

55. GWCA0701 A Double Blind, Randomized, Placebo Controlled, Parallel Group Dose-Range Exploration Study of Sativex® in Relieving Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy.

-start 2008 -2010

CRO – Sanofi-Aventis

56. EFC10547 - A Multinational, Randomized, Double-Blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer -start 2008

57. “A Multinational ,Randomized, Double-blind Study,Comparing the Efficacy of Aflibercept Once Every 2 Weeks versus Placebo in Patients with Metastatic Colorectal Cancer (MCRC) Treated with Irinotecan/5FU Combination (FOLFIRI) afterfailure of an oxaliplatin based regimen” VELOUR Start – jan 2009 58. A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy 2008-2010

CRO - AMGEN

59. A PRIORI: A Prospective Data Audit from Patients Treated with Aranesp Due to Chemotherapy Induced Anaemia 2007-2010



CRO - Clinical Trial Co.

60. A Phase III randomised , multicenter ,double-blind, therapeutic equivalence study of biosimilar G-CSF (Pliva/Mayne filgrastim) versus Neupogen (filgrastim-Amgen) in subjects receiving doxorubicin and docetaxelas combination therapy for breast cancer.

-start 2007 -2010

61. Open label, multi-center, Phase II Study on Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Leuprorelin 6M Implant HEXAL in Patients with Hormone Dependent Prostatic Cancer -start 2008 - 2011

CRO - Kendle

62. SUCCEED - A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas -start 2008 - 2010

CRO – ICON

63. A multinational, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of AVE5026 in the prevention of venous thromboembolism (VTE) in cancer patients at high risk for VTE and who are undergoing chemotherapy -start - jan 2009

CRO – PSI PHARMA SUPPORT

64. A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain 2012-2014

65. A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy 2012-2015

66. Phase II, Double-blind, Randomized, Two-stage, Placebo-controlled Proof of Concept Study in Colorectal Cancer Patients Receiving 5-FU Based Chemotherapy to Assess the Efficacy of Elsiglutide (ZP1846) Administered s.c. in the Prevention of Chemotherapy Induced Diarrhea (CID) 2010-2014 CRO - ICON PLC 67. A Randomized, Double-blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine 2012-2015

68. A Study of Chemotherapy and Ramucirumab vs. Chemotherapy Alone in Second Line Nonsmall Cell Lung Cancer Participants Who Received Prior First Line Platinum Based Chemotherapy 2013-2016



69. GAMMA-1 (GS-US-296-1080) – A Phase 3 Randomized, DoubleBlind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma 2016-2018

CRO-PPDI

70. A Randomized, Open-label, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma 2009-2010

71. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy AMG 20070782 2010-2017

72. AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY - S-1 -Protocol No.: TPU-S1303 2011-2014

73. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG 102) with Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma - Amgen Protocol Number [Rilotumumab (AMG 102)]: 20070622 2013-2015

74. Studiu de fază Ib/2 de extensie și de creștere a dozei de NC-6004 (nanoparticule de cisplatină) plus gemcitabină la pacienți cu tumori solide în stadiu avansat sau cancer pulmonar nonmicrocelular scuamos, cancer al căilor biliare și cancer al vezicii urinare MODICUM NC-60004004A – NANO-CARRIER 2016-2018

75. Un studiu de faza III, deschis, randomizat pentru evaluarea Atezolizumab (MPDL3280A, Anticorp Anti-PDL-1) în combinație cu carboplatin sau cisplatin –pemetrexed comparativ cu administrarea de carbopatin sau cisplatin +pemetrexed la pacienți cu cancer pulmonar nonmicrocelular non-scuamos în stadiul IV și care nu au primit anterior chimioterapie – GO29438 2016-2018

CRO-COVANCE

76. An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy 2012-2016

CRO- QUINTILES (IQVIA)

77. A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-positive Primary Breast Cancer (Affinity) 2011-2015



78. A Phase 3, Multicenter, Randomized, Open-label Trial to Evaluate the Survival Benefit of Panitumumab and Best Supportive Care, Compared to Best Supportive Care Alone, in Subjects With Chemorefractory Wild-type KRAS Metastatic Colorectal Cancer 2012-2016

79. A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long-term Safety and Efficacy of Darbepoetin Alfa Administered at 500 µg Once-Every-3-Weeks in Anemic Subjects With Advanced Stage Non-small Cell Lung Cancer Receiving Multi-cycle Chemotherapy 2011-2015

80. A PHASE III, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR-POSITIVE AND HER2NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAVE DISEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY - GO29058 2016-2018

CRO- INCResearch

81. Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT

CRO- BRISTOL-MYERS-SQUIBB

82. An Open-Label Randomized Phase III Trial of BMS-936558 Versus Docetaxel in Previously Treated Advanced or Metastatic Squamous Cell Non-small Cell Lung Cancer (NSCLC) 2013-2017

83. A Randomized, Open-Label, Phase 3 Study of BMS-936558 vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior AntiAngiogenic Therapy 2014-2016

CRO - ACCELSIORS

84. A PHASE III, RANDOMIZED, ACTIVE CONTROLLED, ASSESSORBLINDED STUDY OF SAFETY AND EFFICACY OF PEGYLATED APOFILGRASTIM VERSUS US AND EU LICENSED NEULASTA® IN SUBJECTS WITH STAGE IIA, IIB OR IIIA BREAST CANCER RECEIVING TAC ANTICANCER CHEMOTHERAPY IN ADJUVANT SETTING 2015-2017

85. A Randomised, Multi-Centre, Assessor-Blinded, Active-Controlled, Parallel-Group, Equivalence Phase III Study Comparing the Safety and Efficacy of USV Pegfilgrastim and Neulasta® in Breast Cancer Patients Undergoing Myelosuppressive Chemotherapy 2016-2017

CRO-VERUMEDU

86. Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma 2014-2016



87. A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS ADJUVANT THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study) 2013-2015

CRO- CHILTERN CLINICAL RESEARCH

88. MANTA – A randomized Phase II study of Fulvestrant in combination with either the dual mTOR inhibitor AZD2014, or Everolimus or Fulvestrant alone in Estrogen receptor – positive advanced or metastatic breast cancer - 009175QM 2016-2018

89. PAKT - A Phase II, Double Blind, Randomised, Placebo-Controlled Study of the AKT Inhibitor AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer - 009246QM 2016-2018

CRO – SYNEOS HEALTH

90. A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER 2016-2018

2023-present – CRO -ICON, PAREXEL,

91. A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

92. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients with Child-Pugh Class B7 Cirrhosis

93. A PHASE 3 TRIAL OF FIANLIMAB (REGN3767, ANTI-LAG-3) CEMIPIMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA

94. A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants with Previously-Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma



Constantin Volovat

<https://orcid.org/0000-0003-1582-0135>

Country

Romania

Other IDs

ResearcherID: N-6580-2013 (<http://www.researcherid.com/rid/N-6580-2013>)

Loop profile: 730756 (http://loop.frontiersin.org/people/730756/overview?referrer=orcid_profile)

ResearcherID: O-5396-2019 (<https://publons.com/researcher/O-5396-2019>)

Employment (4)

Grigore T. Popa University of Medicine and Pharmacy:

Iasi, iasi, RO

2019-02-22 to present | lecturer (Oncology)

Employment

Source:Constantin Volovat

Center of Oncology Euroclinic: Iasi, Iasi, RO

2011-07-08 to present | medical director (medical oncology)

Employment

Source:Constantin Volovat

Center of Medical Oncology: Iasi, Iasi, RO

2000-07-07 to 2011-07-06 | manager (medical oncology)

Employment

Source:Constantin Volovat

Clinic St.Spiridon Universitary Hospital: Iasi, Iasi, RO

1994-06-06 to 2000-07-06 | head ambulatory hospital (medical oncology)

Employment

Source:Constantin Volovat



Education and qualifications (2)

Carol Davila University of Medicine and Pharmacy:

Bucharest, Bucharest, RO

1991-07-05 to present | specialist in medical oncology (medical oncology)

Qualification

Source:Constantin Volovat

Grigore T. Popa University of Medicine and Pharmacy:

Iasi, Iasi, RO

2008-05-10 to 2012-09-11 | PhD

Education

Source:Constantin Volovat

Membership and service (2)

European Society for Medical Oncology: Viganello, TI, CH

2008-06-05 to present | FULL MEMBER

Membership

Source:Constantin Volovat

American Society of Clinical Oncology: Alexandria, VA, US

2001-05-22 to present | FULL MEMBER INTERNATIONAL

Membership

Source:Constantin Volovat

Works (60 of 60)



**Improved Personalised Neuroendocrine Tumours'
Diagnosis Predictive Power by New Receptor
Somatostatin Image Processing Quantification.**

Journal of personalized medicine

2021-10-17 | journal-article

PMID: 34683183

PMC: PMC8539645

DOI: 10.3390/jpm11101042

Source:Constantin Volovat

**Predictors of the response to nivolumab immunotherapy
in the second or subsequent lines for metastatic non-
small cell lung cancers.**

Experimental and therapeutic medicine

2021-04-14 | journal-article

PMID: 33936262

PMC: PMC8082661

DOI: 10.3892/etm.2021.10037

Source:Constantin Volovat

**Nanomedicine to modulate immunotherapy in cutaneous
melanoma (Review).**

Experimental and therapeutic medicine

2021-03-23 | journal-article

PMID: 33815608

PMC: PMC8014970

DOI: 10.3892/etm.2021.9967

Source:Constantin Volovat

**MiRNA and LncRNA as Potential Biomarkers in Triple-
Negative Breast Cancer: A Review.**

Frontiers in oncology

2020-11-20 | journal-article

PMID: 33330019

PMC: PMC7716774

DOI: 10.3389/fonc.2020.526850

Source:Constantin Volovat



Oncogenic mechanisms in renal insufficiency.

Clinical kidney journal

2020-10-23 | journal-article

PMID: 33623673

PMC: PMC7886561

DOI: 10.1093/ckj/sfaa122

Source:Constantin Volovat

Predictive Value of HPV, p53, and p16 in the Post-Treatment Evolution of Malignant Tumors of the Oropharynx and Retromolar Trigone–Oropharynx Junction

Medicina

2020-10 | journal-article

DOI: 10.3390/medicina56100542

Source:Multidisciplinary Digital Publishing Institute

A multicenter, single-arm, basket design, phase II study of NC-6004 plus gemcitabine in patients with advanced unresectable lung, biliary tract, or bladder cancer

Oncotarget

2020-08-18 | journal-article

DOI: 10.18632/oncotarget.27684

Part of ISSN: 1949-2553

Source:Constantin Volovat

Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors

Nuclear Medicine Communications

2020-05-21 | journal-article

DOI: 10.1097/mnm.0000000000001198

Part of ISSN: 0143-3636

Source:Constantin Volovat



**Contribution of Pathology in Surgical Oncology in
Malignant Tumors of the Salivary Glands**

Revista de Chimie

2020-02-07 | journal-article

DOI: 10.37358/rc.20.1.7869

Part of ISSN: 0034-7752

Part of ISSN: 2668-8212

Source:Constantin Volovat

Primitive Gastric Lymphoma - a Series of 3 Cases

Revista de Chimie

2020-02-07 | journal-article

DOI: 10.37358/rc.20.1.7868

Part of ISSN: 0034-7752

Part of ISSN: 2668-8212

Source:Constantin Volovat

**Correlations between HPV, p53 and p16 in malignancies
involving the retromolar trigone-oropharynx junction.**

*Romanian journal of morphology and embryology = Revue
roumaine de morphologie et embryologie*

2019-01-01 | journal-article

PMID: 31912096

Source:Constantin Volovat

**"Liquid Biopsy" - Is it a Feasible Option in Colorectal
Cancer?**

Chirurgia

2019 | journal-article

DOI: 10.21614/chirurgia.114.2.162

Part of ISSN: 1221-9118

Source:Constantin Volovat

**Clinically relevant bleeding in cancer patients treated for
venous thromboembolism from the CATCH study**

Journal of Thrombosis and Haemostasis


2018-06 | journal-article

DOI: 10.1111/jth.14007

Part of ISSN: 1538-7933

Part of ISSN: 1538-7836

Source:Constantin Volovat



Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer

New England Journal of Medicine

2017-07-27 | journal-article

DOI: 10.1056/nejmoa1704174

Part of ISSN: 0028-4793

Part of ISSN: 1533-4406

Source:Constantin Volovat

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

New England Journal of Medicine

2017-07-13 | journal-article

DOI: 10.1056/nejmoa1703643

Part of ISSN: 0028-4793

Part of ISSN: 1533-4406

Source:Constantin Volovat

Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

2016-08-08 | journal-article

PMID: 27501966

DOI: 10.1007/s00520-016-3347-3

Source:Constantin Volovat

The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis

Journal of Chemotherapy

2016-05-03 | journal-article

DOI: 10.1179/1973947815y.00000000042

Part of ISSN: 1120-009X

Part of ISSN: 1973-9478

Source:Constantin Volovat



Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy

SpringerPlus

2015-12 | journal-article

DOI: 10.1186/s40064-015-1067-7

Part of ISSN: 2193-1801

Source:Constantin Volovat

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

New England Journal of Medicine

2015-11-05 | journal-article

DOI: 10.1056/nejmoa1510665

Part of ISSN: 0028-4793

Part of ISSN: 1533-4406

Source:Constantin Volovat

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial

The Lancet Oncology

2015-07 | journal-article

DOI: 10.1016/s1470-2045(15)00021-2

Part of ISSN: 1470-2045

Source:Constantin Volovat

Concomitance of pancreatic and neuroendocrine breast tumour - simple coincidence or not?

Endocrine Abstracts

2015-05-01 | journal-article

DOI: 10.1530/endoabs.37.ep1343

Part of ISSN: 1479-6848

Source:Constantin Volovat



Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study

The Lancet Oncology

2015-05 | journal-article

DOI: 10.1016/s1470-2045(15)70127-0

Part of ISSN: 1470-2045

Source:Constantin Volovat

Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study

The Lancet Oncology

2015-03 | journal-article

DOI: 10.1016/s1470-2045(15)70046-x

Part of ISSN: 1470-2045

Source:Constantin Volovat

Efficacy of Lipegfilgrastim (Lipeg) and Pegfilgrastim (Peg) in Breast Cancer Patients Receiving Chemotherapy (Ctx) Stratified By Status, Age, and Disease Stageby Status, Age, and Disease Stage

Annals of Oncology

2014-09 | journal-article

DOI: 10.1093/annonc/mdu356.16

Part of ISSN: 0923-7534

Source:Constantin Volovat

Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non-Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study

Journal of Thoracic Oncology

2014-08 | journal-article

DOI: 10.1097/jto.0000000000000227

Part of ISSN: 1556-0864

Source:Constantin Volovat



KRAS,NRASandBRAFmutations in Greek and Romanian patients with colorectal cancer: a cohort study

BMJ Open

2014-05 | journal-article

DOI: 10.1136/bmjopen-2013-004652

Part of ISSN: 2044-6055

Part of ISSN: 2044-6055

Source:Constantin Volovat

Pancreatic neuroendocrine tumour with a silent long evolution: case report

Endocrine Abstracts

2014-04-17 | journal-article

DOI: 10.1530/endoabs.35.p592

Part of ISSN: 1479-6848

Source:Constantin Volovat

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

The Lancet Oncology

2014-01 | journal-article

DOI: 10.1016/s1470-2045(13)70510-2

Part of ISSN: 1470-2045

Source:Constantin Volovat

SECOND-LINE CHEMOTHERAPY WITH GEMCITABINE AND OXALIPLATIN IN COMBINATION WITH LOCO-REGIONAL HYPERTHERMIA (EHY-2000) IN PATIENTS WITH REFRACTORY METASTATIC PANCREATIC CANCER - PRELIMINARY RESULTS OF A PROSPECTIVE TRIAL

Romanian Reports on Physics

2014 | journal-article

WOSUID: WOS:000333776200019

Source:Web of Science

**STUDY 20070782: RANDOMIZED PHASE 3 TRIAL OF THE
LONG-TERM SAFETY OF DARBEPOETIN ALFA IN
PATIENTS WITH NON-SMALL CELL LUNG CANCER
(NSCLC) WITH CHEMOTHERAPY-INDUCED ANEMIA (CIA)**

Journal of Thoracic Oncology

2014 | journal-article

WOSUID: WOS:000341688500123

Source: Web of Science

**THE RESULTS OF COMBINATION OF IFOSFAMID AND
LOCOREGIONAL HYPERTHERMIA (EHY 2000) IN
PATIENTS WITH ADVANCED ABDOMINAL SOFT-TISSUE
SARCOMA AFTER RELAPSE OF FIRST LINE
CHEMOTHERAPY**

Romanian Reports on Physics

2014 | journal-article

WOSUID: WOS:000333776200020

Source: Web of Science

**Efficacy and safety of balugrastim compared with
pegfilgrastim in patients with breast cancer receiving
chemotherapy.**

Clinical breast cancer

2013-10-25 | journal-article

PMID: 24485296

DOI: 10.1016/j.clbc.2013.10.001

Source: Constantin Volovat

**A Randomized, Double-blind, Placebo-controlled Study to
Assess QTc Interval Prolongation of Standard Dose
Aflibercept in Cancer Patients Treated With Docetaxel**


Journal of Cardiovascular Pharmacology

2013-06 | journal-article

DOI: 10.1097/fjc.0b013e31828b73ff

Part of ISSN: 0160-2446

Source: Constantin Volovat



Efficacy and safety of balugrastim in chemotherapy-induced neutropenia: Integrated analysis of two randomized phase III studies.

Journal of Clinical Oncology

2013-05-20 | journal-article

DOI: 10.1200/jco.2013.31.15_suppl.e17572

Part of ISSN: 0732-183X

Part of ISSN: 1527-7755

Source:Constantin Volovat

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

The Lancet Oncology

2013-05 | journal-article

DOI: 10.1016/s1470-2045(13)70102-5

Part of ISSN: 1470-2045

Source:Constantin Volovat

Clinical outcome according to tumor HER2 status and EGFR expression in advanced gastric cancer patients from the EXPAND study

Journal of Clinical Oncology

2013 | journal-article

WOSUID: WOS:000335419601396

Source:Web of Science

Efficacy and safety of balugrastim in chemotherapy-induced neutropenia: Integrated analysis of two randomized phase III studies.

Journal of Clinical Oncology

2013 | journal-article

WOSUID: WOS:000335419604441

Source:Web of Science

Incidence of bone pain in patients with breast cancer treated with balugrastim or pegfilgrastim: An integrated analysis from the phase II and III studies

European Journal of Cancer

2013 | journal-article

WOSUID: WOS:000326843603070

Source:Web of Science



Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

New England Journal of Medicine

2012-12-20 | journal-article

DOI: 10.1056/nejmoa1205511

Part of ISSN: 0028-4793

Part of ISSN: 1533-4406

Source:Constantin Volovat

Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer

New England Journal of Medicine

2012-02-16 | journal-article

DOI: 10.1056/nejmoa1108898

Part of ISSN: 0028-4793

Part of ISSN: 1533-4406

Source:Constantin Volovat

Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy

Journal of Clinical Oncology

2012 | journal-article

WOSUID: WOS:000318009804311

Source:Web of Science

Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy

Journal of Clinical Oncology

2012 | journal-article

WOSUID: WOS:000318009804113

Source:Web of Science

Randomized phase 2 study of efatutazone in combination with carboplatin and paclitaxel as first-line therapy for metastatic non-small cell lung cancer (NSCLC)

Cancer Research

2012 | journal-article

DOI: 10.1158/1538-7445.AM2012-4606

WOSUID: WOS:000209701601377

Source:Web of Science



**Immunotherapy with PD-1 Inhibitor Nivolumab in
Recurrent/Metastatic Platinum Refractory Head and Neck
Cancers—Early Experiences from Romania and Literature
Review**

Diagnostics

2023-08 | journal-article

DOI: 10.3390/diagnostics13162620

Source: Multidisciplinary Digital Publishing Institute

**Multi-fractal modeling of curcumin release mechanism
from polymeric nanomicelles.**

Drug delivery

2022-12-01 | journal-article

PMID: 36062523

PMC: PMC9448400

DOI: 10.1080/10717544.2022.2118402

Source: Constantin Volovat

**Use of Personalized Biomarkers in Metastatic Colorectal
Cancer and the Impact of AI**

Cancers

2022-10 | journal-article

DOI: 10.3390/cancers14194834

Source: Multidisciplinary Digital Publishing Institute

**Is High Expression of Claudin-7 in Advanced Colorectal
Carcinoma Associated with a Poor Survival Rate? A
Comparative Statistical and Artificial Intelligence Study.**

Cancers

2022-06-13 | journal-article

PMID: 35740581

PMC: PMC9221359

DOI: 10.3390/cancers14122915

Source: Constantin Volovat



Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer.

Journal of immunology research

2022-05-04 | journal-article

PMID: 35571568

PMC: PMC9095399

DOI: 10.1155/2022/1636908

Source:Constantin Volovat

The Landscape of Nanovectors for Modulation in Cancer Immunotherapy.

Pharmaceutics

2022-02-11 | journal-article

PMID: 35214129

PMC: PMC8875018

DOI: 10.3390/pharmaceutics14020397

Source:Constantin Volovat

Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease.

Journal of clinical medicine

2022-01-26 | journal-article

PMID: 35160069

PMC: PMC8836903

DOI: 10.3390/jcm11030616

Source:Constantin Volovat

Theoretical model for the diclofenac release from PEGylated chitosan hydrogels.

Drug delivery

2021-12-01 | journal-article

PMID: 33501878

PMC: PMC7850333

DOI: 10.1080/10717544.2021.1876181

Source:Constantin Volovat



**Quality of Life of Women With Breast Cancer Treated in
Adjuvant Setting With Tamoxifen or Aromatase Inhibitors**

European Journal of Cancer

2011 | journal-article

DOI: 10.1016/S0959-8049(11)71605-7

WOSUID: WOS:000295752801331

Source: Web of Science

**Pharmacokinetics, immunogenicity and bioactivity of the
therapeutic antibody catumaxomab intraperitoneally
administered to cancer patients**

British Journal of Clinical Pharmacology

2010-02-01 | journal-article

DOI: 10.1111/j.1365-2125.2010.03635.x

Part of ISSN: 0306-5251

Part of ISSN: 1365-2125

Source: Constantin Volovat

**KRAS status and efficacy of first-line treatment of patients
with metastatic colorectal cancer (mCRC) with FOLFOX
with or without cetuximab: The OPUS experience**

Journal of Clinical Oncology

2008-05-20 | journal-article

DOI: 10.1200/jco.2008.26.15_suppl.4000

Part of ISSN: 0732-183X

Part of ISSN: 1527-7755

Source: Constantin Volovat

**Pharmacokinetics and in vivo stability of intraperitoneally
administered therapeutic antibody catumaxomab**

Journal of Clinical Oncology

2008 | journal-article

DOI: 10.1200/JCO.2008.26.15_SUPPL.14006

WOSUID: WOS:000208457400751

Source: Web of Science



The opus study: Predictive value of KRAS status on clinical outcome in patients with metastatic colorectal cancer treated with either FOLFOX4 or FOLFOX4 plus cetuximas

Annals of Oncology

2008 | journal-article

WOSUID: WOS:000257951800034

Source: Web of Science

Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) in the first-line treatment of metastatic colorectal cancer (mCRC): a large-scale phase 11 study, OPUS

European Journal of Cancer, Supplement

2007 | journal-article

DOI: 10.1016/S1359-6349(07)70932-1

WOSUID: WOS:000250204000783

Source: Web of Science

The assessment of recurrence in multimodal treated rectal cancer. Retrospective study

Annals of Oncology

2006 | journal-article

WOSUID: WOS:000239782000351

Source: Web of Science

Supportive care of the metastatic patients

2ND BALKAN CONGRESS OF ONCOLOGY

1999 | journal-article

WOSUID: WOS:000081930300002

Source: Web of Science

Immunotherapy with PD-1 Inhibitor Nivolumab in Recurrent/Metastatic Platinum Refractory Head and Neck Cancers: The Early Experience of Two Academic Center

working-paper

DOI: 10.20944/preprints202305.0561.v1

Source: Multidisciplinary Digital Publishing Institute

Record last modified Aug 28, 2023, 6:55:12 PM

